Oculis (OCS) Study presentation summary
Event summary combining transcript, slides, and related documents.
Study presentation summary
30 Oct, 2026Market need and product rationale
2024 dry-eye prescription market in G7 countries was shown at $5bn; calcineurin inhibitors represented 68% of U.S. prescriptions, LFA-1 antagonists 19%, and other treatments 13%.
Only 13% of patients experienced lasting relief after 12 months on current treatments; 85%–90% discontinued within 180 days.
Licaminlimab is an anti-TNFα antibody fragment formulated as an eye drop; its lower molecular weight is designed to enhance ocular penetration.
The candidate targets inflammation and apoptosis; a TNFR1 genetic biomarker is intended to identify patients more likely to respond.
Phase 2 evidence and biomarker
Three Phase 2 trials were completed: two symptom-focused studies (85 and 134 patients) and the RELIEF signs study (122 patients); results were described as consistently positive.
Phase 2 results showed a more pronounced treatment effect in TNFR1 genotype-positive patients: 5x greater in signs and 7x in symptoms.
In RELIEF, Day 43 inferior corneal staining difference versus vehicle was -0.59 in the TNFR1 group (n=12 vs. 11; 90% CI -1.165 to -0.017), compared with -0.12 in the full population; analyses were preliminary.
Exploratory analysis found a significant association between TNFR1 and ocular discomfort response at Day 29 (P<0.0001); high responders represented 18% on licaminlimab versus 5% on vehicle (P=0.018).
Safety and tolerability
Phase 2a/2b safety data showed at least one TEAE in 18.8% on licaminlimab and 13.8% on vehicle; study-eye ocular TEAEs occurred in 11.5% and 10.2%, respectively.
No deaths were reported; treatment-related serious TEAEs were 0% in both groups, and drop comfort was described as consistent with artificial tears.
Latest events from Oculis
- Privosegtor advances neuroprotection while licaminlimab tests biomarker-guided dry-eye care.OCS
Stifel 2026 Healthcare Conference 2026 - PREDICT-1 readout nears as privosegtor advances across neuroprotection indications.OCS
3rd Annual Guggenheim Healthcare Innovation Conference - Late-stage trials advance as $252.0M in cash supports runway into 2H 2029.OCS
Q3 2026 - ACUITY signals support a registrational optic neuritis program for privosegtor.OCS
Euretina Innovation Spotlight (EIS) 2026 Presentation - Phase III programs in dry eye and optic neuritis advance, with MS and NAION expansion planned.OCS
2026 Global Healthcare Conference - Precision medicine and targeted trials drive clinical and commercial strategy, with strong funding.OCS
H.C. Wainwright 28th Annual Global Investment Conference - Privosegtor and Licaminlimab trials advance, with strong cash reserves supporting long-term growth.OCS
Q2 2026 - Late-stage neuro-ophthalmic and ophthalmic programs advance toward pivotal milestones with strong financial backing.OCS
Corporate presentation - Positive clinical results and precision medicine advances set the stage for major milestones in 2024–2025.OCS
H.C. Wainwright 26th Annual Global Investment Conference